Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTW2BQF4)

• DOT Name: Hemoglobin subunit alpha (HBA1)
• Synonyms: Alpha-globin; Hemoglobin alpha chain
• Gene Name: HBA1
• Related Disease:
  Alpha thalassemia
  Stroke
  Acute erythroid leukemia
  Acute myocardial infarction
  Beta-thalassemia intermedia
  Bipolar disorder
  Cardiac arrest
  Cardiovascular disease
  Childhood myelodysplastic syndrome
  Cystic fibrosis
  Delta-beta-thalassemia
  Erythrocytosis, familial, 7
  Familial Mediterranean fever
  Hemolytic anemia
  Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome
  HIV infectious disease
  Hydrops fetalis
  IRIDA syndrome
  Iron-deficiency anemia
  Leukemia
  Melorheostosis
  Methemoglobinemia
  Nephropathy
  Non-immune hydrops fetalis
  Polycystic kidney disease 1
  Primary familial polycythemia due to EPO receptor mutation
  Prostate neoplasm
  Sickle-cell anaemia
  Thalassemia
  Vascular disease
  Cerebral infarction
  Hemoglobinopathy
  High blood pressure
  Hypochromic microcytic anemia
  Myocardial ischemia
  Polycythemia
  Polycythemia vera
  Hb Bart's hydrops fetalis
  Hemoglobin H disease
  Hemoglobin M disease
  Intellectual disability
  Myelodysplastic syndrome
  Autosomal dominant polycystic kidney disease
  Brain neoplasm
  Carcinoma
  Heinz body anemia
  Methemoglobinemia, alpha type
  Undifferentiated carcinoma
• UniProt ID: HBA_HUMAN
• PDB ID: 1A00 ; 1A01 ; 1A0U ; 1A0Z ; 1A3N ; 1A3O ; 1A9W ; 1ABW ; 1ABY ; 1AJ9 ; 1B86 ; 1BAB ; 1BBB ; 1BIJ ; 1BUW ; 1BZ0 ; 1BZ1 ; 1BZZ ; 1C7B ; 1C7C ; 1C7D ; 1CLS ; 1CMY ; 1COH ; 1DKE ; 1DXT ; 1DXU ; 1DXV ; 1FDH ; 1FN3 ; 1G9V ; 1GBU ; 1GBV ; 1GLI ; 1GZX ; 1HAB ; 1HAC ; 1HBA ; 1HBB ; 1HBS ; 1HCO ; 1HDB ; 1HGA ; 1HGB ; 1HGC ; 1HHO ; 1IRD ; 1J3Y ; 1J3Z ; 1J40 ; 1J41 ; 1J7S ; 1J7W ; 1J7Y ; 1JY7 ; 1K0Y ; 1K1K ; 1KD2 ; 1LFL ; 1LFQ ; 1LFT ; 1LFV ; 1LFY ; 1LFZ ; 1LJW ; 1M9P ; 1MKO ; 1NEJ ; 1NIH ; 1NQP ; 1O1I ; 1O1J ; 1O1K ; 1O1L ; 1O1M ; 1O1N ; 1O1O ; 1O1P ; 1QI8 ; 1QSH ; 1QSI ; 1QXD ; 1QXE ; 1R1X ; 1R1Y ; 1RPS ; 1RQ3 ; 1RQ4 ; 1RQA ; 1RVW ; 1SDK ; 1SDL ; 1SHR ; 1SI4 ; 1THB ; 1UIW ; 1VWT ; 1XXT ; 1XY0 ; 1XYE ; 1XZ2 ; 1XZ4 ; 1XZ5 ; 1XZ7 ; 1XZU ; 1XZV ; 1Y01 ; 1Y09 ; 1Y0A ; 1Y0C ; 1Y0D ; 1Y0T ; 1Y0W ; 1Y22 ; 1Y2Z ; 1Y31 ; 1Y35 ; 1Y45 ; 1Y46 ; 1Y4B ; 1Y4F ; 1Y4G ; 1Y4P ; 1Y4Q ; 1Y4R ; 1Y4V ; 1Y5F ; 1Y5J ; 1Y5K ; 1Y7C ; 1Y7D ; 1Y7G ; 1Y7Z ; 1Y83 ; 1Y85 ; 1Y8W ; 1YDZ ; 1YE0 ; 1YE1 ; 1YE2 ; 1YEN ; 1YEO ; 1YEQ ; 1YEU ; 1YEV ; 1YFF ; 1YG5 ; 1YGD ; 1YGF ; 1YH9 ; 1YHE ; 1YHR ; 1YIE ; 1YIH ; 1YVQ ; 1YVT ; 1YZI ; 1Z8U ; 2D5Z ; 2D60 ; 2DN1 ; 2DN2 ; 2DN3 ; 2DXM ; 2H35 ; 2HBC ; 2HBD ; 2HBE ; 2HBF ; 2HBS ; 2HCO ; 2HHB ; 2HHD ; 2HHE ; 2M6Z ; 2W6V ; 2W72 ; 2YRS ; 3B75 ; 3D17 ; 3D7O ; 3DUT ; 3HHB ; 3HXN ; 3IA3 ; 3IC0 ; 3IC2 ; 3KMF ; 3NL7 ; 3NMM ; 3ODQ ; 3ONZ ; 3OO4 ; 3OO5 ; 3OVU ; 3P5Q ; 3QJB ; 3QJC ; 3QJD ; 3QJE ; 3R5I ; 3S48 ; 3S65 ; 3S66 ; 3SZK ; 3WCP ; 3WHM ; 4FC3 ; 4HHB ; 4IJ2 ; 4L7Y ; 4M4A ; 4M4B ; 4MQC ; 4MQG ; 4MQH ; 4MQI ; 4MQJ ; 4MQK ; 4N7N ; 4N7O ; 4N7P ; 4N8T ; 4NI0 ; 4NI1 ; 4ROL ; 4ROM ; 4WJG ; 4X0L ; 4XS0 ; 5E29 ; 5E6E ; 5E83 ; 5EE4 ; 5HU6 ; 5HY8 ; 5JDO ; 5KDQ ; 5KSI ; 5KSJ ; 5NI1 ; 5SW7 ; 5U3I ; 5UCU ; 5UFJ ; 5URC ; 5VMM ; 5WOG ; 5WOH ; 5X2R ; 5X2S ; 5X2T ; 5X2U ; 6BB5 ; 6BNR ; 6BWP ; 6BWU ; 6DI4 ; 6HAL ; 6HBW ; 6HK2 ; 6KA9 ; 6KAE ; 6KAH ; 6KAI ; 6KAO ; 6KAP ; 6KAQ ; 6KAR ; 6KAS ; 6KAT ; 6KAU ; 6KAV ; 6KYE ; 6L5V ; 6L5W ; 6L5X ; 6L5Y ; 6LCW ; 6LCX ; 6NBC ; 6NBD ; 6NQ5 ; 6TB2 ; 6XD9 ; 6XDT ; 6XE7 ; 7AET ; 7AEU ; 7AEV ; 7CUE ; 7DY3 ; 7DY4 ; 7JJQ ; 7JXZ ; 7JY0 ; 7JY1 ; 7JY3 ; 7K4M ; 7PCF ; 7PCH ; 7PCQ ; 7QU4 ; 7UD7 ; 7UD8 ; 7UF6 ; 7UF7 ; 7UVB ; 7VDE ; 7XGY ; 8DOV ; 8EGI ; 8FDK ; 8FDL ; 8FDM ; 8FDN
• Pfam ID: PF00042
• Sequence:
  MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG
  KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP
  AVHASLDKFLASVSTVLTSKYR
• Function: Involved in oxygen transport from the lung to the various peripheral tissues.; [Hemopressin]: Hemopressin acts as an antagonist peptide of the cannabinoid receptor CNR1. Hemopressin-binding efficiently blocks cannabinoid receptor CNR1 and subsequent signaling.
• Tissue Specificity: Red blood cells.
• KEGG Pathway:
  African trypanosomiasis (hsa05143)
  Malaria (hsa05144)
• Reactome Pathway:
  Erythrocytes take up oxygen and release carbon dioxide (R-HSA-1247673)
  Scavenging of heme from plasma (R-HSA-2168880)
  Cytoprotection by HMOX1 (R-HSA-9707564)
  Heme signaling (R-HSA-9707616)
  Erythrocytes take up carbon dioxide and release oxygen (R-HSA-1237044)

Molecular Interaction Atlas (MIA) of This DOT

48 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Alpha thalassemia	DIS5XGK0	Definitive	Autosomal recessive	[1]
Stroke	DISX6UHX	Definitive	Genetic Variation	[2]
Acute erythroid leukemia	DISZFC1O	Strong	Altered Expression	[3]
Acute myocardial infarction	DISE3HTG	Strong	Altered Expression	[4]
Beta-thalassemia intermedia	DISYQ0NL	Strong	Biomarker	[5]
Bipolar disorder	DISAM7J2	Strong	Genetic Variation	[6]
Cardiac arrest	DIS9DIA4	Strong	Genetic Variation	[7]
Cardiovascular disease	DIS2IQDX	Strong	Biomarker	[8]
Childhood myelodysplastic syndrome	DISMN80I	Strong	Genetic Variation	[9]
Cystic fibrosis	DIS2OK1Q	Strong	Biomarker	[10]
Delta-beta-thalassemia	DIS6CWYR	Strong	Genetic Variation	[11]
Erythrocytosis, familial, 7	DISJ0LQ0	Strong	Autosomal dominant	[12]
Familial Mediterranean fever	DISVP5WP	Strong	Genetic Variation	[13]
Hemolytic anemia	DIS803XQ	Strong	Genetic Variation	[14]
Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome	DISD21FA	Strong	Biomarker	[15]
HIV infectious disease	DISO97HC	Strong	Genetic Variation	[16]
Hydrops fetalis	DISD9BBF	Strong	Genetic Variation	[17]
IRIDA syndrome	DISPN8YW	Strong	Genetic Variation	[18]
Iron-deficiency anemia	DIS0VQYF	Strong	Genetic Variation	[19]
Leukemia	DISNAKFL	Strong	Altered Expression	[3]
Melorheostosis	DISIMCL3	Strong	Altered Expression	[20]
Methemoglobinemia	DISEWENH	Strong	Biomarker	[21]
Nephropathy	DISXWP4P	Strong	Biomarker	[22]
Non-immune hydrops fetalis	DISPUY8C	Strong	Biomarker	[23]
Polycystic kidney disease 1	DIS9FB3R	Strong	Genetic Variation	[24]
Primary familial polycythemia due to EPO receptor mutation	DISFVI97	Strong	Biomarker	[25]
Prostate neoplasm	DISHDKGQ	Strong	Biomarker	[26]
Sickle-cell anaemia	DIS5YNZB	Strong	Genetic Variation	[2]
Thalassemia	DIS76XZB	Strong	Genetic Variation	[27]
Vascular disease	DISVS67S	Strong	Biomarker	[28]
Cerebral infarction	DISR1WNP	moderate	Biomarker	[29]
Hemoglobinopathy	DISCT4GX	moderate	Genetic Variation	[30]
High blood pressure	DISY2OHH	moderate	Biomarker	[31]
Hypochromic microcytic anemia	DIS0RMTQ	moderate	Genetic Variation	[18]
Myocardial ischemia	DISFTVXF	moderate	Altered Expression	[32]
Polycythemia	DIS8B6VW	moderate	Biomarker	[29]
Polycythemia vera	DISB5FPO	moderate	Biomarker	[29]
Hb Bart's hydrops fetalis	DISU3KCF	Supportive	Autosomal recessive	[33]
Hemoglobin H disease	DISHFWO5	Supportive	Autosomal recessive	[33]
Hemoglobin M disease	DISGMVWE	Supportive	Autosomal dominant	[34]
Intellectual disability	DISMBNXP	Disputed	Genetic Variation	[35]
Myelodysplastic syndrome	DISYHNUI	Disputed	Genetic Variation	[9]
Autosomal dominant polycystic kidney disease	DISBHWUI	Limited	Genetic Variation	[24]
Brain neoplasm	DISY3EKS	Limited	Genetic Variation	[36]
Carcinoma	DISH9F1N	Limited	Biomarker	[37]
Heinz body anemia	DISVMFK6	Limited	Autosomal dominant	[38]
Methemoglobinemia, alpha type	DIS35QA7	Limited	Autosomal dominant	[1]
Undifferentiated carcinoma	DISIAZST	Limited	Biomarker	[37]

This DOT Affected the Drug Response of 1 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Urea	DMUK75B	Approved	Hemoglobin subunit alpha (HBA1) increases the Renal failure chronic ADR of Urea.	[60]

18 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the expression of Hemoglobin subunit alpha (HBA1).	[39]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Hemoglobin subunit alpha (HBA1).	[40]
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Hemoglobin subunit alpha (HBA1).	[41]
Cisplatin	DMRHGI9	Approved	Cisplatin increases the expression of Hemoglobin subunit alpha (HBA1).	[42]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Hemoglobin subunit alpha (HBA1).	[43]
Quercetin	DM3NC4M	Approved	Quercetin decreases the expression of Hemoglobin subunit alpha (HBA1).	[44]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Hemoglobin subunit alpha (HBA1).	[45]
Menadione	DMSJDTY	Approved	Menadione affects the expression of Hemoglobin subunit alpha (HBA1).	[46]
Folic acid	DMEMBJC	Approved	Folic acid decreases the expression of Hemoglobin subunit alpha (HBA1).	[47]
Capecitabine	DMTS85L	Approved	Capecitabine decreases the expression of Hemoglobin subunit alpha (HBA1).	[48]
Orlistat	DMRJSP8	Approved	Orlistat decreases the expression of Hemoglobin subunit alpha (HBA1).	[49]
Urethane	DM7NSI0	Phase 4	Urethane increases the expression of Hemoglobin subunit alpha (HBA1).	[51]
Resveratrol	DM3RWXL	Phase 3	Resveratrol increases the expression of Hemoglobin subunit alpha (HBA1).	[52]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate increases the expression of Hemoglobin subunit alpha (HBA1).	[53]
Cetilistat	DMWAHTN	Phase 3	Cetilistat decreases the expression of Hemoglobin subunit alpha (HBA1).	[54]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol decreases the expression of Hemoglobin subunit alpha (HBA1).	[55]
Acetaldehyde	DMJFKG4	Investigative	Acetaldehyde increases the expression of Hemoglobin subunit alpha (HBA1).	[57]
Deguelin	DMXT7WG	Investigative	Deguelin increases the expression of Hemoglobin subunit alpha (HBA1).	[58]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Flucloxacillin	DMNUWST	Approved	Flucloxacillin affects the binding of Hemoglobin subunit alpha (HBA1).	[50]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the methylation of Hemoglobin subunit alpha (HBA1).	[56]
D-glucose	DMMG2TO	Investigative	D-glucose increases the glycation of Hemoglobin subunit alpha (HBA1).	[59]

References

• [1] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [2] Common -globin variants modify hematologic and other clinical phenotypes in sickle cell trait and disease.PLoS Genet. 2018 Mar 28;14(3):e1007293. doi: 10.1371/journal.pgen.1007293. eCollection 2018 Mar.
• [3] Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias.Br J Haematol. 1998 Sep;102(5):1335-7. doi: 10.1046/j.1365-2141.1998.00904.x.
• [4] Glycated hemoglobin level is an independent predictor of major adverse cardiac events after nonfatal acute myocardial infarction in nondiabetic patients: A retrospective observational study.Medicine (Baltimore). 2017 May;96(18):e6743. doi: 10.1097/MD.0000000000006743.
• [5] Genotype-phenotype association analysis identifies the role of globin genes in modulating disease severity of thalassaemia intermedia in Sri Lanka.Sci Rep. 2019 Jul 12;9(1):10116. doi: 10.1038/s41598-019-46674-y.
• [6] Hemoglobins emerging roles in mental disorders. Metabolical, genetical and immunological aspects.Int J Dev Neurosci. 2017 Oct;61:73-85. doi: 10.1016/j.ijdevneu.2017.06.007. Epub 2017 Jul 8.
• [7] TNFSF/TNFRSF cytokine gene expression in sickle cell anemia: Up-regulated TNF-like cytokine 1A (TL1A) and its decoy receptor (DcR3) in peripheral blood mononuclear cells and plasma.Cytokine. 2019 Nov;123:154744. doi: 10.1016/j.cyto.2019.154744. Epub 2019 Jun 28.
• [8] Association of A1C with cardiovascular disease and metabolic syndrome in Asian Indians with normal glucose tolerance.Diabetes Care. 2007 Jun;30(6):1527-32. doi: 10.2337/dc06-2414. Epub 2007 Mar 10.
• [9] Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome.Blood. 2004 Feb 15;103(4):1518-20. doi: 10.1182/blood-2003-09-3222. Epub 2003 Oct 23.
• [10] Glucose intolerance in children with cystic fibrosis.J Pediatr. 2003 Feb;142(2):128-32. doi: 10.1067/mpd.2003.5.
• [11] Rapid detection of Spanish (delta beta)zero-thalassemia deletion by polymerase chain reaction.Blood. 1992 Sep 15;80(6):1582-5.
• [12] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [13] Regional mapping of the gene for familial Mediterranean fever on human chromosome 16p13.Am J Med Genet. 1993 Jul 1;46(6):689-93. doi: 10.1002/ajmg.1320460619.
• [14] Compound heterozygosity for two alpha-globin gene defects, Hb Taybe (alpha 1; 38 or 39 minus Thr) and a poly A mutation (alpha 2; AATAAA-->AATAAG), results in a severe hemolytic anemia.Am J Hematol. 1994 Nov;47(3):198-202. doi: 10.1002/ajh.2830470310.
• [15] Molecular mechanism of high hemoglobin F production in Southeast Asian-type hereditary persistence of fetal hemoglobin.Int J Hematol. 2006 Apr;83(3):229-37. doi: 10.1532/IJH97.E0509.
• [16] Human gene copy number variation and infectious disease.Hum Genet. 2014 Oct;133(10):1217-33. doi: 10.1007/s00439-014-1457-x. Epub 2014 Jun 5.
• [17] Validation of the immunochromatographic strip for -thalassemia screening: a multicenter study.Transl Res. 2015 Jun;165(6):689-95. doi: 10.1016/j.trsl.2014.10.013. Epub 2014 Nov 5.
• [18] Alpha-globin gene mutation spectrum in patients with microcytic hypochromic anemia from Mazandaran Province, Iran.J Clin Lab Anal. 2020 Jan;34(1):e23018. doi: 10.1002/jcla.23018. Epub 2019 Sep 2.
• [19] Hematological phenotypes in children according to the -globin genotypes.Blood Cells Mol Dis. 2018 Mar;69:102-106. doi: 10.1016/j.bcmd.2017.10.003. Epub 2017 Nov 3.
• [20] CACCC and GATA-1 sequences make the constitutively expressed alpha-globin gene erythroid-responsive in mouse erythroleukemia cells.Nucleic Acids Res. 1996 Jan 15;24(2):342-7. doi: 10.1093/nar/24.2.342.
• [21] Hemoglobin M Iwate is caused by a C----T transition in codon 87 of the human alpha 1-globin gene.Hum Genet. 1987 Jan;75(1):53-5. doi: 10.1007/BF00273839.
• [22] Elevated hemoglobin glycation index identify non-diabetic individuals at increased risk of kidney dysfunction.Oncotarget. 2017 Jun 19;8(45):79576-79586. doi: 10.18632/oncotarget.18572. eCollection 2017 Oct 3.
• [23] Rapid prenatal diagnosis of common beta-thalassemia mutations in Southeast Asia using pyrosequencing.Prenat Diagn. 2013 Nov;33(11):1017-22. doi: 10.1002/pd.4183. Epub 2013 Jul 21.
• [24] Human-mouse homologies in the region of the polycystic kidney disease gene (PKD1).Genomics. 1992 May;13(1):35-8. doi: 10.1016/0888-7543(92)90198-2.
• [25] Hemoglobins with high oxygen affinity leading to erythrocytosis. New variants and new concepts.Hemoglobin. 2005;29(2):91-106.
• [26] Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men.Prostate Cancer Prostatic Dis. 2008;11(3):264-9. doi: 10.1038/sj.pcan.4501022. Epub 2007 Oct 16.
• [27] Prenatal diagnosis of - and -thalassemias in southern Thailand.Int J Hematol. 2020 Feb;111(2):284-292. doi: 10.1007/s12185-019-02761-4. Epub 2019 Oct 28.
• [28] Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia.Br J Haematol. 2012 Nov;159(3):352-9. doi: 10.1111/bjh.12034. Epub 2012 Sep 7.
• [29] Hb Kanagawa [alpha 40(C5)Lys----Met]: a new alpha chain variant with an increased oxygen affinity.Hemoglobin. 1992;16(1-2):1-10. doi: 10.3109/03630269209005670.
• [30] Atypical Prenatal Ultrasound Presentation and Neuropathological Findings in a Neonate With Alpha Thalassemia Major: A Case Report.Pediatr Dev Pathol. 2019 Mar-Apr;22(2):166-170. doi: 10.1177/1093526618817655. Epub 2018 Dec 14.
• [31] A combination of two novel alpha globin variants Hb Bridlington (HBA1) and Hb Taybe (HBA2) resulting in severe hemolysis, pulmonary hypertension, and death.Hematology. 2015 Jan;20(1):50-2. doi: 10.1179/1607845414Y.0000000164. Epub 2014 Apr 10.
• [32] Postmortem mRNA expression patterns in left ventricular myocardial tissues and their implications for forensic diagnosis of sudden cardiac death.Mol Cells. 2014 Mar;37(3):241-7. doi: 10.14348/molcells.2014.2344. Epub 2014 Mar 19.
• [33] Clinical Practice Guidelines for Rare Diseases: The Orphanet Database. PLoS One. 2017 Jan 18;12(1):e0170365. doi: 10.1371/journal.pone.0170365. eCollection 2017.
• [34] Concise review: methemoglobinemia. Am J Hematol. 1993 Jan;42(1):7-12. doi: 10.1002/ajh.2830420104.
• [35] Refinement of the genetic cause of ATR-16.Hum Genet. 2007 Nov;122(3-4):283-92. doi: 10.1007/s00439-007-0399-y. Epub 2007 Jun 28.
• [36] Hemoglobins, Hemorphins, and 11p15.5 Chromosomal Region in Cancer Biology and mmunity with Special Emphasis for Brain Tumors.J Neurol Surg A Cent Eur Neurosurg. 2016 May;77(3):247-57. doi: 10.1055/s-0035-1566120. Epub 2016 Mar 2.
• [37] cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.Carcinogenesis. 2002 Oct;23(10):1561-8. doi: 10.1093/carcin/23.10.1561.
• [38] Hyperunstable hemoglobin Toyama [alpha 2 136(H19)Leu----Arg beta 2]: detection and identification by in vitro biosynthesis with radioactive amino acids. Hemoglobin. 1987;11(6):539-56. doi: 10.3109/03630268709027870.
• [39] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [40] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [41] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [42] Real-time monitoring of cisplatin-induced cell death. PLoS One. 2011;6(5):e19714. doi: 10.1371/journal.pone.0019714. Epub 2011 May 16.
• [43] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [44] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [45] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [46] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [47] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [48] Gene expression responses reflecting 5-FU-induced toxicity: Comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022 Dec 1;371:17-24. doi: 10.1016/j.toxlet.2022.09.013. Epub 2022 Sep 29.
• [49] Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.
• [50] Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury. Toxicol Sci. 2023 Mar 20;192(1):106-116. doi: 10.1093/toxsci/kfad015.
• [51] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [52] Resveratrol induces human K562 cell apoptosis, erythroid differentiation, and autophagy. Tumour Biol. 2014 Jun;35(6):5381-8. doi: 10.1007/s13277-014-1701-y. Epub 2014 Feb 15.
• [53] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [54] Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan;18(1):108-15. doi: 10.1038/oby.2009.155. Epub 2009 May 21.
• [55] Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications?. Diabetes Care. 1991 Jan;14(1):68-72. doi: 10.2337/diacare.14.1.68.
• [56] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [57] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [58] Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.
• [59] Ascorbic acid and protein glycation initro. Chem Biol Interact. 2015 Oct 5;240:154-62.
• [60] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.